CapMan Buyout exits Pharmia to Labomar
Funds managed by CapMan Buyout have sold Pharmia Holding Oy, a leading Finnish contract manufacturer of dietary supplements and medical devices, to Labomar.
CapMan invested in Pharmia in 2021 and has since focused on growing the company’s business and market position in the Nordics. Today, the company is the leading contract manufacturer within dietary supplements and medical devices in the Nordics with a turnover of approximately 20 million euros and 85 employees. The company’s growth has been driven by a strategic focus on medical devices and probiotics, while simultaneously investing in R&D capabilities and operational efficiency improvements.
“During CapMan Buyout’s ownership period, Pharmia has successfully executed its growth strategy. I want to thank Pharmia’s management and personnel as well as my board colleagues for making this a successful investment. I am convinced that Labomar is the right partner for supporting the growth of Pharmia in the future,” says Anders Björkell, Partner at CapMan Buyout.
“I want to thank CapMan for their strong support over the past years. As a next step we are thrilled to be part of the Labomar family. This acquisition marks a strategic step forward in our mission to expand our footprint in the Nordic region and strengthen our capabilities in the development of high-quality food supplements and medical devices. Labomar’s expertise and values align seamlessly with ours, and together we look forward to driving innovation and delivering even greater value to our partners and customers,” comments Petteri Laaksomo, CEO of Pharmia.
Labomar is a leading European manufacturer of food supplements, medical devices and functional cosmetics, and is owned by Charterhouse Capital Partners. The company is headquartered in Italy with operations in Spain and Canada as well.
“We are proud of this new acquisition. Pharmia is a solid and well-structured company, with an approach and vision that we immediately recognised as being closely aligned with those of Labomar. The know-how and experience of its team represent an added value that will further contribute to the growth of our Group. The integration of Pharmia will also allow us to strengthen our presence in a strategically important geographic market and to consolidate our position in a key sector such as probiotics, thereby creating new synergies and further expanding our offering,” says Walter Bertin, founder and CEO of Labomar.
For more information, please contact:
Anders Björkell, Partner, CapMan Buyout, +358 40 537 7566
Petteri Laaksomo, CEO, Pharmia, +358 50 552 5255
About CapMan
CapMan is a leading Nordic private asset expert with an active approach to value creation and 6.5 billion euros in assets under management. As one of the private equity pioneers in the Nordics we have developed hundreds of companies and assets creating significant value for over three decades. Our objective is to provide attractive returns and innovative solutions to investors by enabling change across our portfolio companies. An example of this is greenhouse gas reduction targets that we have set under the Science Based Targets initiative in line with the 1.5°C scenario and our commitment to net-zero GHG emissions by 2040. We have a broad presence in the unlisted market through our local and specialised teams. Our investment strategies cover real estate and infrastructure assets, real asset debt, natural capital and minority and majority investments in portfolio companies. We also provide wealth management solutions. Altogether, CapMan employs around 200 professionals in Helsinki, Jyväskylä, Stockholm, Copenhagen, Oslo, London, Luxembourg, and Düsseldorf. We are listed on Nasdaq Helsinki since 2001. Learn more at www.capman.com.
About Pharmia
Pharmia is Finland’s leading contract manufacturer specialised in the development and manufacture of food supplements and medical devices (CE-marked products). Pharmia enhances people’s well-being by creating innovative solutions for their customers, which they produce with a concept “from idea to product”. Pharmia’s passion for well-being guides them to be more than just a contract manufacturer – they are a partner that implements and enables their customers’ success. https://pharmia.fi/en/.
